Impact of FDG PET on patients with differentiated thyriod cancer who present with thyroglobulin and negative 131I scan

Journal of Nuclear Medicine

Volumn 42, Issue 1, 2001, Pages 71-76

  Schluter B ^a   Bohuslavizki, K H ^a   Beyer, W ^a   Plotkin, M ^a   Buchert, R ^a   Clausen, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

FDG PET; Thyroid cancer; Treatment strategy

Indexed keywords

FLUORODEOXYGLUCOSE; IODINE 131; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTILLATION CAMERA; THYROID CANCER; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035133895     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Imaging in thyroid cancer
2. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma
3. Pulmonary metastasis of differentiated thyroid carcinoma: Treatment results in 101 patients
4. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose
5. 131I whole body scans and elevated serum thyroglobulin levels
6. 18F-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy
7. FDG-PET can localize metastatic sites of differentiated thyroid carcinoma in I-131 scan negative patients
8. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors
9. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer
10. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer
11. Strengths and weaknesses of F-18-FDG-PET in the follow-up of high-risk thyroid cancer patients with negative diagnostic I-131 scans
12. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans
13. Fluorine-18-fluorodeoxyglucose (FDG) PET for detection of occultly metastasized thyroid carcinoma
14. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine- 131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
15. Follow-up of differentiated thyroid cancer: What is the value of FDG and sestamibi in the diagnostic algorithm?
16. 131I
17. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer
18. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer
19. Clinical value of positron emission tomography (PET) in oncologic questions: Results of an interdisciplinary consensus conference
20. Positron emission tomography in oncology
21. Histological verification of FDG-positive findings in differentiated thyroid carcinoma
22. Indication of FDG-PET in differentiated thyroid cancer
23. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer
24. 18F-FDG-PET on treatment in patients with differentiated thyroid cancer
25. Treatment consequence of FDG-PET in patients with differentiated thyroid carcinoma
26. 18F]-fluorodeoxyglucose uptake in tumors: Kinetic vs. steady-state methods with reference to insulin
27. PET in oncology: Image analysis using a computer monitor versus standardized film documentation
28. Follow-up after radioiodine treatment of differentiated thyroid cancer
29. Over expression of glucose transporter 1 as a sign of increased malignancy in thyroid carcinoma: An immunohistochemical study
30. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: Comparison with the expression of the Ki-67 antigen
31. Long-term follow-up and therapeutic results in patients with low-risk differentiated thyroid carcinoma
32. 131I-accumulating pulmonary and bone metastases of differentiated thyroid cancer with low serum thyroglobulin levels: An exception in tumor follow-up ?
33. Postsurgical management of differentiated thyroid carcinoma
34. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer